Immunocor raised $320MM in a private financing round to support its anti-cancer platform. That’s a lot of money for a single financing – in fact, it is the largest private fundraising by a European biotechnology company. What’s the attraction? Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)